In this project, a biopharma company needed to compare the impurity profile of their mAb biosimilar to that of the originator product. Interestingly, SWATH LC-MS analysis identified several host cell proteins (HCPs) in the originator drug product batches, not found in the biosimilar.
The client is a multinational biopharmaceutical company focusing on developing best-in-class biosimilar medicines. Their observations showed a difference in drug stability when comparing originator to biosimilar where the latter was more stable. The client had a particular interest in investigating the impurity profile to explain the stability differences.
Why you should look for problematic HCPs
Especially one HCP, identified in the originator, caught our eye. Cathepsin is a protease that may decrease the stability of the therapeutic protein. This specific protease belongs to a group of enzymes known to cleave various recombinant proteins, such as antibody fragments, monoclonal antibodies, bispecific antibodies, and fusion proteins.
Therefore, cathepsin is considered potentially problematic, and you should identify and remove it to increase shelf life. Moreover, increased stability is a safety issue and often affects the Cost of Goods Sold (COGS). Thus, better stability may result in significant economic savings during the life span of the drug product.
No problematic HCPs detected in the client’s biosimilar
We also analyzed the biosimilar product by mass spectrometry, and the comparison results are in the table below. Interestingly, we only detected cathepsin in the originator and provided our client with data showing that their product did not contain any detectable HCPs known to be problematic. This knowledge thus supplied them with extra ammunition for regulatory documentation. Also, they now had further sales arguments on why you should choose their product over the originator.